Old is the existence of psychosis and varied are its presentations. Efforts to understand this enigma, as well as to treat the sufferer have been puzzling humanity since time as old as the problem itself. So far, trials have been done with innumerable options including a number of pharmacological agents starting from those of ancient days through typical antipsychotics to atypical ones in later times. But problems came hand-in-glove with each of these options. As extrapyramidal side effects of typical antipsychotics compelled clinicians to move towards the atypical ones, these newer, so-called novel agents have brought with them a gamut of adversities, the various metabolic side effects.
No comments:
Post a Comment